The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
Placebo will be given on the same schedule as the propranolol regime.
University of Missouri-Columbia
Columbia, Missouri, United States
RECRUITINGChange in Neuropsychological Assessment Battery Naming Test
Time frame: Day 1, 4 Weeks, 8 Weeks, 10 Weeks, 14 Weeks,18 Weeks
Change in State-Trait Anxiety Inventory for Adults
The State-Trait Anxiety scores range from 20-40. A higher score indicates more anxiety.
Time frame: Day 1, 4 Weeks, 8 Weeks, 10 Weeks,14 Weeks,18 Weeks
Change in Semantic Word Fluency Tasks
The Semantic Word Fluency task measures the subject's ability to name as many items in a minute in a given category. The total number of correct and non-repeated responses are totaled for each category. There is no minimum or maximum score. Higher scores indicate better word fluency.
Time frame: Day 1, 8 Weeks,18 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.